Assoc @ RA Cap | ex @Pillar_VC & @CivilizationVC | Postdoc @nygenome | PhD @UChicago | @NCICancerBio F99/K00 Fellow | @NSFGRFP | @NucleateHQ | Immigrant 🇨🇴
New York, NY
Joined February 2019
- Tweets3.5K
- Following1.3K
- Followers718
- Likes6.9K
Pinned Tweet
Still trying to wrap my mind around the fact that I have been awarded the @NCICancerBio F99/K00. I can’t shake the feeling that someone like me (Latinx immigrant) has earned such an honor, but I know it’s not just mine. Eternally thankful to everyone who has taken a chance on me.
Santiago Acero-Bedoya, PhD (he/him) retweeted
We're launching a program to get free or heavily discounted Claude usage to scientists, through Claude Teams for Science.
If you're a student or researcher in academia or a non profit org, ask your PI to apply. We're starting with 10,000 seats and will expand from there.
Starting today, 10,000 scientists across every field, from math to chemistry to physics and more, can get Claude through our new Claude Team plan for scientists. Standard seats are free, and premium seats with 5x usage limits are $15 per month, an 80% discount, for one year.
Claude is becoming increasingly capable of scientific work, with recent progress on problems from advanced physics calculations to protein design. Alongside that progress, we've been investing in the research community: Claude Science launched in June, and our AI for Science program funds high-impact projects with free credits. Today's expansion builds on both.
Principal investigators (or equivalent) at academic and nonprofit research institutions can sign up, then add the researchers in their group. Over the coming months, we plan to extend the program well beyond the initial 10,000 seats.
Learn more: claude.com/programs/team-pla…
Santiago Acero-Bedoya, PhD (he/him) retweeted
Here is our updated database of grants for early careers researchers in all fields.
It goes way beyond traditional NIH and NSF funding opportunities. We list 428 types of grants.
Download it here: research.jhu.edu/rdt/funding…
Santiago Acero-Bedoya, PhD (he/him) retweeted
Today I'd like to honor the memory of my mentor and friend, Roger Tsien, born 1952 February 1. Today would have been Roger's 74th birthday.
Most know Roger for his 2008 Chemistry Nobel Prize with Shimomura and Chalfie. Roger made GFP into the versatile imaging method it is now.
Santiago Acero-Bedoya, PhD (he/him) retweeted
Fanning the flames: IFN-Îł fuels CAR-T inflammation and cytopenia: doi.org/10.1172/JCI201161
A Commentary by Stefanie R. Bailey & Marcela V. Maus @MarcelaMaus @harvardmed on Payal Goala et al.: doi.org/10.1172/JCI194631
Santiago Acero-Bedoya, PhD (he/him) retweeted
🔬 Want to understand how drugs are developed and made affordable?
Join NPLB Biotech Fellows → live sessions, real-world projects, and a global network spanning every top 50+ U.S. university.
👉 Apply now to join us this spring: nopatientleftbehind.org/fell…
#NPLBFellowship #BiotechSocialContract #AffordableInnovation #Biotech
Santiago Acero-Bedoya, PhD (he/him) retweeted
Raj and I just dropped the 2026 Semper Maior report. 20 years of M&A lessons + a massive deep dive into deal data since 2019. Lot's of hard-earned lessons in here.
Read it on your way to JPM before your strategic meetings. Good luck out there!
#JPM2026
Santiago Acero-Bedoya, PhD (he/him) retweeted
We analyzed impact of CMS's "experimental" GLOBE/GUARD policies to cap US prices at what other countries pay (answer: backfire). Note: doesn't lower what patients pay... that's a function what insurance gets away with charging sick people out of pocket. rapport.racap.com/all-storie…
Santiago Acero-Bedoya, PhD (he/him) retweeted
Single-cell genomics finally makes it into the clinic. “Can you show me on the UMAP where it hurts?”
Santiago Acero-Bedoya, PhD (he/him) retweeted
Miriam Merad’s 20-year quest to understand one cell is starting to rewrite the rules of cancer immunotherapy statnews.com/2025/10/28/miri…
Santiago Acero-Bedoya, PhD (he/him) retweeted
How do the 3 longest-living vertebrates live so long?
The Greenland shark modifies p53 and reduces protein stress
The bowhead whale boosts DNA repair
And the rougheye rockfish alters IGF signalling and controls inflammation
Santiago Acero-Bedoya, PhD (he/him) retweeted
Drug spending isn't the driver of increasing healthcare costs in any OECD country. Drug spend grew slowly for 25 years (yellow line), while overall healthcare spending outpaces it (blue line).
New IQVIA report: iqvia.com/-/media/iqvia/pdfs…
Santiago Acero-Bedoya, PhD (he/him) retweeted
bioRxiv has a dedicated section for negative results.
Use it.
Share negative results.
Your colleagues will appreciate it.
Santiago Acero-Bedoya, PhD (he/him) retweeted
PSA: Stop calling macrophages in tissue M1 or M2. These are not states that exist in biology. The only use of M1 is a macrophage cultured ex vivo with LPS and IFNg; and for M2: IL-4/13/10. Macrophages in tissues are highly complex and diverse and do not resemble either of the aforementioned M1/M2 states. M1/M2 language causes confusion and sets the field back. Refer to your macrophages by the molecules they express and the cytokines they make.
Santiago Acero-Bedoya, PhD (he/him) retweeted
🧠Today is #WorldBrainDay.
Over 8M Americans live with neurodegenerative diseases like Alzheimer’s, Huntington’s, and ALS.
#Biotech teams are working on better treatments. If you invest or pay premiums, you may already be helping.
🎥Watch here:
Santiago Acero-Bedoya, PhD (he/him) retweeted
3.8 million Americans are living with breast cancer.
1 in 8 women will be diagnosed.
#Biotech startups are developing treatments, and if you pay insurance or invest, you may be helping.
🔗 nopatientleftbehind.org/the-…
#CommunityQuest #BreastCancer #FixInsurance #ProtectInnovation
Santiago Acero-Bedoya, PhD (he/him) retweeted
Millions suffer from rheumatoid arthritis.
Biotech is working on cures, but patients still face high out-of-pocket costs.
If you're saving for retirement, you're likely helping fund this research.
Let’s #FixInsurance and #protectUSinnovation during #ArthritisAwarenessMonth.
🎥 nopatientleftbehind.org/our-…
#ArthritisAwareness
Santiago Acero-Bedoya, PhD (he/him) retweeted
100K people live with #CysticFibrosis. New treatments offer hope, but not for all.
Meet biotech innovators working toward a cure—and hear how we support their mission.
Price controls risk progress. Patients need access, not high OOP costs.
#CF #biotech #CFAwarenessMonth
Santiago Acero-Bedoya, PhD (he/him) retweeted
🎥 New video: Meet biotech innovators working to cure ovarian cancer.
By paying your insurance premiums—and saving for retirement—you help efforts like these to vanquish many diseases.
Price controls would kill this progress. Insurance reform—not R&D cuts—is the solution.
Santiago Acero-Bedoya, PhD (he/him) retweeted
3 million Americans are diagnosed with skin cancer each year.
Our new Community Quest video highlights biotech innovators working on new treatments.
Hear from them why we need to #FixInsurance so that patients can access their prescribed medicines at low out-of-pocket costs.